康寧傑瑞(09966.HK)治療晚期實體瘤藥相關臨床試驗於澳洲獲批

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

康寧傑瑞(09966.HK)治療晚期實體瘤藥相關臨床試驗於澳洲獲批

阿思達克 12-08 12:11

康寧傑瑞製藥－Ｂ(09966.HK)公布，其自主研發的用於治療人表皮生長因子受體2表達的晚期，或轉移性實體瘤的JSKN033的I/II期臨床試驗，已獲得澳洲Bellberry臨床研究倫理委員會批准。

Relevant Stocks

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

康寧傑瑞(09966.HK)治療晚期實體瘤藥相關臨床試驗於澳洲獲批

Services

About Us

Agreement Statement